FDA approves wegovy use to treat liver disease

The decision was based on results from a phase 3 test, which showed that a larger percentage of people who took the drug surpassed steatohepatitis and did not show worsement of liver scars compared to placebo volunteers.

In the US, Mash affects approximately one in 20 people. It is often asymptomatic or causes non -specific symptoms in the early stages, which may result in late diagnosis.

When untreated, the disease can progress to serious and sometimes fatal outcomes.

Novo Nordisk also requested regulatory approval from the European Union in February and Japan in May.

Wegovy is already indicated to reduce the risk of cardiovascular events in adults with heart disease or obesity.

*With information from Dow Jones Newswires